A defective gene linked to obesity appears to affect impulse control and food choices. And this could explain why people with the gene have so much trouble maintaining a healthy weight as they age, a new U.S. study says.
Middle-aged and older people with obesity-associated variants of the FTO gene tend to gain weight, according to researchers from the National Institutes of Health. Moreover, scans detected reduced function in brain regions that govern impulsivity and perception of food texture and taste, the researchers found.
Sure enough, people who carry one or two copies of the FTO variant show increased intake of high-calorie or fatty food as they age.
There may be a common biological factor underlying both the risk for obesity during aging as well as obesity-related behavior like your ability to resist impulse eating.
Many studies have tied certain versions of the FTO gene to chronic obesity, but doctors have struggled to determine why the gene affects a person's risk of obesity.
These types of studies are important to disentangle the mechanism of why FTO is associated with obesity, but it's only one piece of a huge puzzl.
In the United States, more than one-third of adults aged 65and over are obese, according to background information in the study.
About 45 percent of people in this study had at least one copy of the pro-obesity FTO variant, Thambisetty said, which tracks with the white population in the United States. About 16 percent of people had two copies of the gene, which confers an even greater risk of obesity.
The study focused on nearly 700 participants, including 69 people who agreed to annual PET scans to gather additional information regarding their brain structure and function. At the start of the study, average age was 46.
All were participating in the Baltimore Longitudinal Study of Aging, one of the longest running studies of human aging in North America.
They first confirmed that body mass index increased in those with one or two copies of the FTO gene variant. They then compared brain PET scans of patients with the FTO variant with scans of non-carriers, looking for differences in brain function over time.
They found people with the gene variant had reduced function in their medial prefrontal cortex, a region thought to be important in controlling impulses and response to the taste and texture of food.
In a final step, the team reviewed data gathered on participants' personality and diet. The group at increased genetic risk for obesity showed a greater tendency to impulsivity as well as a greater intake of fatty foods during aging.
The effect appears to increase with the number of copies. "We see a dose effect, where these changes in impulsivity or a preference for fatty foods increase with multiple copies of the gene," Thambisetty said.
The findings are published May 27, 2014 in the journal Molecular Psychiatry.
If these results pan out in additional studies, they mean that people who have a greater genetic risk of obesity face an uphill battle to maintain a healthy weight.
This should not be an excuse, but it has to be a partial explanation why intelligent and motivated individuals struggle so much, because they are fighting their biology and it's uncomfortable to fight your own biology.
However, a genetic predisposition to obesity does not mean one is doomed to obesity.
You may be genetically susceptible, but by living a healthy lifestyle you can overcome your genetics. You are not destined to be obese.
Previous studies have shown that people can overcome the obesity risk posed by the FTO gene through regular exercise.
SOURCES: Madhav Thambisetty, M.D., Ph.D., chief, Clinical and Translational Neuroscience, U.S. National Institute on Aging's Laboratory of Behavioral Neuroscience; Ruth Loos, Ph.D., director, Genetics of Obesity and Related Metabolic Traits Program, Charles R. Bronfman Institute of Personalized Medicine at the Icahn School of Medicine at Mount Sinai, New York City; Steven Lamm, M.D., medical director, Preston Robert Tisch Center for Men's Health, NYU Langone Medical Center, New York City; May 27, 2014, Molecular Psychiatry
No comments:
Post a Comment